Last checked at 15 Oct 2020 13:51
Synairgen plc
("Synairgen" or the "Company")
Director Dealing/PDMR Announcement
Further to the announcement earlier today regarding the Placing, the Company makes the below announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014) in respect of the exercise of options by Richard Marsden, CEO of the Company, and John Ward, Finance Director of the Company.
Enquiries:
Synairgen plc +44 (0) 23 8051 2800
Richard Marsden (Chief Executive Officer)
John Ward (Finance Director)
finnCap - Nominated Adviser and Joint Bookrunner +44 (0) 20 7220 0500
Geoff Nash / James Thompson / Charlie Beeson (Corporate Finance)
Alice Lane / Sunila de Silva (ECM)
Numis - Joint Bookrunner +44 (0) 20 7260 1000
James Black / Freddie Barnfield / Duncan Monteith
Consilium Strategic Communications - Financial Media and Investor +44 (0) 20 3709 5700
Relations Adviser
Mary-Jane Elliott / Sue Stuart / Olivia Manser
About Synairgen
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma, COPD and COVID-19, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
a) | Name | Richard Marsden |
2. | Reason for notification | |
a) | Position / status | Chief Executive Officer |
b) | Initial notification / amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Synairgen plc |
b) | LEI | 213800IMMTOPPDF8HD24 |
4. | Details of the transaction(s): | |
a) | Description of the financial instrument Identification code | Options over ordinary shares of 1p each GB00B0381Z20 |
b) | Nature of the transaction | Exercise of options over Ordinary Shares
|
c) | Price(s) and volume(s) | 386,842 Ordinary shares of 1p each |
d) | Aggregated information Aggregated volume Price | n/a |
e) | Date of the transaction | 15 October 2020 |
f) | Place of the transaction | London Stock Exchange |
1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
a) | Name | John Ward |
2. | Reason for notification | |
a) | Position / status | Finance Director |
b) | Initial notification / amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Synairgen plc |
b) | LEI | 213800IMMTOPPDF8HD24 |
4. | Details of the transaction(s): | |
a) | Description of the financial instrument Identification code | Options over ordinary shares of 1p each GB00B0381Z20 |
b) | Nature of the transaction | Exercise of options over Ordinary Shares
|
c) | Price(s) and volume(s) | 147,330 Ordinary shares of 1p each |
d) | Aggregated information Aggregated volume Price | n/a |
e) | Date of the transaction | 15 October 2020 |
f) | Place of the transaction | London Stock Exchange |